Article thumbnail

Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

By R. Vermeij, N. Leffers, S. H. van der Burg, C. J. Melief, T. Daemen and H. W. Nijman


Approximately 50% of human malignancies carry p53 mutations, which makes it a potential antigenic target for cancer immunotherapy. Adoptive transfer with p53-specific cytotoxic T-lymphocytes (CTL) and CD4+ T-helper cells eradicates p53-overexpressing tumors in mice. Furthermore, p53 antibodies and p53-specific CTLs can be detected in cancer patients, indicating that p53 is immunogenic. Based on these results, clinical trials were initiated. In this paper, we review immunological and clinical responses observed in cancer patients vaccinated with p53 targeting vaccines. In most trials, p53-specific vaccine-induced immunological responses were observed. Unfortunately, no clinical responses with significant reduction of tumor-burden have occurred. We will elaborate on possible explanations for this lack of clinical effectiveness. In the second part of this paper, we summarize several immunopotentiating combination strategies suitable for clinical use. In our opinion, future p53-vaccine studies should focus on addition of these immunopotentiating regimens to achieve clinically effective therapeutic vaccination strategies for cancer patients

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A .d eM a r e ,A .J .A .L a m b e c k ,J .R e g t se ta l . ,“ V i r a l vector-based prime-boost immunization regimens: a possibleinvolvementofT-cellcompetition,”GeneTherapy,vol.15,
  2. (2002). A .D eV r i e s ,E .R .F l o r e s ,B .M i r a n d ae ta l . ,“ T a r g e t e dp o i n t mutations of p53 lead to dominant-negative inhibition of wild-type
  3. (2005). A .V .M a k e r ,G .Q .P h a n ,P .A t t i ae ta l . ,“ T u m o rr e g r e s s i o n and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study,”
  4. (2010). A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na¨ ıve patients with advanced melanoma,” Investigational New Drugs.
  5. (2007). A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cellsinhighriskovariancancerpatients,”inProceedingsofthe American Society of Clinical Oncology Annual Meeting,
  6. (2003). A.G.Menon,P.J.K.Kuppen,S.H.VanderBurgetal.,“Safety ofintravenous administration ofa canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients,”
  7. (2003). Achtar et al., “Wild-type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinoma,”
  8. (2007). Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo,”
  9. (1991). Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells,”
  10. (2008). Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation,”
  11. (2008). Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin2,” Vaccine,
  12. and W.R.Heath,“BcellsdirectlytolerizeCD8+Tcells,”Journal of Experimental Medicine,vol.188,no.11,pp.1977–1983,1998.
  13. (2002). Antunes Ferreira et al., “Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man,”
  14. (2008). Arvidsson et al., “Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer,”
  15. (2009). Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival,”
  16. B i j k e r
  17. B i j k e r ,S .J .F .V a nD e nE e d e n ,K .L .F r a n k e n
  18. (2009). C h i a n e s e - B u l l o c k
  19. (2004). Cancer genes and the pathways they control,”
  20. (2004). Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes,”
  21. (2007). Cancer vaccines: moving beyond current paradigms,”
  22. (2006). Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines,”
  23. (2010). Chemotherapy and radiotherapy: cryptic anticancer vaccines,”
  24. (2010). Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice,”
  25. (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stagesmallcell lungcancer,”Clinical Cancer
  26. (2008). Combined modality immunotherapy and chemotherapy: a new perspective,”
  27. (2010). Comparable effectofp53peptide vaccineinadjuvantorpulsedondenritic cells in ovarian cancer patients: a gynecologic oncology groupstudy,”inProceedings oftheAmerican SocietyofClinical Oncology Annual Meeting,
  28. (1995). Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis,”Immunological Reviews,
  29. (2008). CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?”Clinical Cancer Research,vol.14,no.16,pp.
  30. (2008). CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion,”
  31. (2007). DC-based cancer vaccines,”
  32. (2009). Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma,”
  33. (2008). Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy,”
  34. (2009). Disruption of TGF-β signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity,”
  35. (2001). Elsas et al., “Synergism of cytotoxic T lymphocyte-associated antigen 4blockadeanddepletion ofCD25+regulatory Tcells inantitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses,”
  36. (1996). Enhanced tumor outgrowth after peptide vaccination: functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors,”
  37. (2005). Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells,”
  38. (2004). F i g d o r
  39. (2004). Guerrero et al.,“Expression of sperm protein 17 (Sp17) in ovarian cancer,”
  40. (2008). H u n g ,T .C .W u ,A .M o n i e ,a n dR .R o d e n ,“ A n t i g e n -specific immunotherapy of cervical and ovarian cancer,”
  41. (2010). i t s u i ,H .N i s h i k a w a ,D .M u r a o k ae ta l . ,“ T w od i s t i n c t mechanismsofaugmentedantitumoractivity by modulation of immunostimulatory/inhibitory signals,”
  42. (2008). i t v o g e l ,L .A p e t o h ,F .G h i r i n g h e l l i ,F .A n d r ´
  43. (2010). i t v o g e l ,O .K e p p ,L .S e n o v i l l a ,L .M e n g e r ,N .C h a p u t , andG.Kroemer,“Immunogenictumorcelldeathforoptimal anticancer therapy: the calreticulin exposure pathway,”
  44. (2007). Identification of T-cell epitopes for cancer immunotherapy,”
  45. (2009). Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial,”
  46. (2009). Immunogenic and tolerogenic cell death,”
  47. (2009). Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-monocyte colony-stimulating factor and/or IFIN-α2b in advanced metastatic melanoma: eastern cooperative oncology group phase
  48. (2005). Immunologic aspect of ovarian cancer and p53 as tumor antigen,”
  49. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance,”
  50. (2008). Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines,”
  51. (2003). Increase of regulatory T cells in the peripheral blood of cancer patients,”
  52. (2002). Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine,” Clinical Cancer Research,v o l .8 ,n o .5 ,p p .
  53. (2010). J.De Vos VanSteenwijk et al., “Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses,”
  54. (1993). J.G.A.Houbiers,H.W .Nijman,S.H.V anDerBurgetal.,“In vitro induction of human cytotoxic T Iymphocyte responses against peptides of mutant and wild-type p53,”
  55. (2008). L a u w e n ,S .Z w a v e l i n g ,L .D eQ u a r t e le ta l .
  56. (2002). Live or let die: the cell’s response to p53,”
  57. (2010). Low-dose cyclophosphamide treatment impairs regulatory T cells
  58. (2008). M.J.P.Welters,G.G.Kenter,S.J.Piersmaetal.,“Inductionof tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine,”
  59. (2007). Metronomic cyclophosphamideregimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients,”
  60. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis,”
  61. (1994). n g e l o p o u l o u ,E .P .D i a m a n d i s
  62. (2010). Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte
  63. (2009). Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer,”
  64. (2009). NY-ESO-1 DNA vaccine induces T-Cell responses that are suppressed by regulatory
  65. (1998). o e s ,E .I .H .V a nD e rV o o r t ,S .P .S c h o e n b e r g e r et al., “Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells,”
  66. (1991). o l l s t e i n ,D .S i d r a n s k y ,B .V o g e l s t e i n ,a n dC .C .H a r r i s ,
  67. (2009). o n g ,S .S .K w e k ,S .O ’ B r i e ne ta l . ,“ P o t e n t i a t i n g endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and
  68. p53-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+
  69. (2004). Packham et al., “PhaseI clinicaltrial of a human idiotypic p53 vaccine in patients with advanced malignancy,”
  70. (1996). Peptide-based cancer vaccines,”
  71. (2009). Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma,”
  72. Potential target antigens for a universal vaccine in epithelial ovarian cancer,”
  73. (2010). Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial,”
  74. (2008). Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes,”
  75. (2010). r m o t te ta l . ,“ I m p r o v e d survival with ipilimumab in patients with metastatic melanoma,”
  76. (2001). R o s e n b e r g ,“ P r o g r e s si nh u m a nt u m o u ri m m u n o l o g y and immunotherapy,”
  77. (2006). Recombinant viral vectors: cancer vaccines,”
  78. (2000). Recombinant viruses as a tool for therapeutic vaccination against human cancers,”
  79. (2006). Regulatory T cells, tumour immunity and immunotherapy,”
  80. (2009). S p e e t j e n s ,P .J .K .K u p p e n
  81. (2008). S.Kanodia,D.M.DaSilva,andW.M.Kast,“Recent advances in strategies for immunotherapy of human papillomavirusinduced
  82. (2010). Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular
  83. (2000). Surfing the p53 network,”
  84. (2007). T a c k e n ,I .J .M .D eV r i e s ,R .T o r e n s m a ,a n dC .G .F i g d o r , “Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting,”
  85. (2009). T u r t l e ,H .M .S w a n s o n ,N .F u j i i ,E .H .E s t e y ,a n dS .R . Riddell, “A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy,”
  86. (2009). T-regulatory cell modulation: the future of cancer immunotherapy,”
  87. (2008). Targeted therapies to improve tumor immunotherapy,”
  88. (1995). Teillaud et al., “p53 antibodies in patients with various types of cancer: assay, identification, andcharacterization,”Clinical Cancer Research,v ol.1,no .12,
  89. (1998). The central role of CD4+ T cells in the antitumor immune response,”
  90. (2008). The tumor microenvironment and its role in promoting tumor growth,”
  91. (1994). Tolerance, danger, and the extended family,”
  92. (1997). Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes,”
  93. (2009). Tumor vaccines expressing Flt3 ligand synergize with CTLA-4 blockade to reject preimplanted tumors,”
  94. (2001). v a nd e rB u r g ,K .d eC o c k ,a n dA .G .M e n o n ,“ L o n g lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer,”
  95. (2006). v a nd e rB u r g ,M .S .B i j k e r
  96. (2010). Vaccination with autologous dendritic cells pulsed with multiple tumor antigensfortreatment ofpatientswithmalignantmelanoma: results from a phase I/II trial,” Cytotherapy,v o l .1 2 ,n o .6 ,p p .
  97. (2004). Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study,”
  98. (2002). w a v e l i n g ,M .P .M .V i e r b o o m ,S .C .F e r r e i r aM o t ae ta l . , “Antitumor efficacyofwild-type p53-specific CD4+T-helper cells,”
  99. (2007). Zacar´ ı a sF l u c k ,M .J .R i c o ,P .M a t a r